Prohibition Partners · Free weekly briefing
International Cannabis Weekly
The week’s global cannabis news, read through the analyst’s lens — one sentence per story, sourced.
343
7 regions32 stories1 publisher10 countries
Top story
Swiss adult-use cannabis pilot participants to top 15,000
The Department of Health for Basel-Stadt, which launched Switzerland’s first pilot trial last year, has published the interim results for its landmark adult-use pilot study.
CHAdult-uselink no longer available
Europe
8 stories- CSU in Germany wants to monitor cannabis consumption via wastewater
DERegulationlink no longer available
- Germany's legislative overhaul marks turning point for European cannabis
DERegulationlink no longer available
- Flora Growth seeks to acquire Germany-based TruHC pharma GmbH
DEBusiness & Investmentlink no longer available
- Treat It announces expansion to include psychiatric services
GBMedicallink no longer available
- Hemp to play role in UK housing development for exponential sustainability
GBHemp & CBDlink no longer available
- French cooperative opens hemp fibre processing facility against fast fashion
FRHemp & CBDlink no longer available
- Rua Bioscience supplies medical cannabis flower to Germany via AlphaPharma
DEBusiness & Investmentlink no longer available
- European cannabis stocks report
Business of CannabisEvents & Industry
United States
6 stories- Florida voters to decide on cannabis legalisation in November
USAdult-uselink no longer available
- Cannabis operators have US$3.8 billion in delinquent payments in 2023
USBusiness & Investmentlink no longer available
- Canopy Growth gains ISS support for U.S. cannabis market entry vote
USBusiness & Investmentlink no longer available
- Hawaii cannabis advocates push for legalisation ahead of bill deadline
USRegulationlink no longer available
- Minnesota opens applications for hemp grower-processor licences
USHemp & CBDlink no longer available
- Crime concerns stall Kansas medical marijuana proposal until next year
USRegulationlink no longer available
Canada
6 stories- Canada plays crucial role in global cannabis industry expansion
CABusiness & Investmentlink no longer available
- Avicanna reports 314% revenue growth in 2023 audited results
CABusiness & Investmentlink no longer available
- Tilray Brands to announce third quarter 2024 financial results
CABusiness & Investmentlink no longer available
- Indiva considers potential sale among strategic options
CABusiness & Investmentlink no longer available
- Imperial Brands converts CA$123 million debt to Auxly Cannabis shares
CABusiness & Investmentlink no longer available
- IM Cannabis launches premium WAGNERS brand in Canadian adult-use market
CAAdult-uselink no longer available
LATAM & Caribbean
4 stories- Colombia medical cannabis exports grow but fall short of operator expectations
COBusiness & Investmentlink no longer available
- Argentina suspends new cannabis operator registrations temporarily
ARRegulationlink no longer available
- Brazil's Anvisa proposes cannabis flowers for pharmacopoeia
BRMedicallink no longer available
- Medical Marijuana Inc. secures Alzheimer's approval for CBD oil in Brazil
BRMedicallink no longer available
Africa & Middle East
2 stories- Malawi legalises cultivation of local cannabis for industrial and medical use
MWRegulationlink no longer available
- BOL Pharma applies to freeze proceedings after reaching insolvency
Business & Investmentlink no longer available
APAC
1 story- MGC Pharma changes name to Argent BioPharma after shareholder approval
Business & Investmentlink no longer available
Oceania
2 stories- Australia records 14,791 medicinal cannabis approvals in March
AUMedicallink no longer available
- Althea completes staff restructure saving AU$1.5 million annually
AUBusiness & Investmentlink no longer available
Never miss an issue
International Cannabis Weekly in your inbox every week — the global developments that move the market, with the data behind them.
From the research library
Global Medical Cannabis Market Review
14 key international markets, 2025–2030. Sizing, forecasts and regulatory outlook.
From £1,265
View report